VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Bordetella bronchiseptica bscN and cyaA double mutant vaccine
Vaccine Information
  • Vaccine Name: Bordetella bronchiseptica bscN and cyaA double mutant vaccine
  • Target Pathogen: Bordetella bronchiseptica
  • Target Disease: Infectious bronchitis, kennel cough
  • Type: Live, attenuated vaccine
  • Status: Research
  • bscN gene engineering:
    • Type: Gene mutation
    • Description:
    • Detailed Gene Information: Click Here.
  • cyaA gene engineering:
    • Type: Gene mutation
    • Description:
    • Detailed Gene Information: Click Here.
  • Preparation: An isogenic mutant of RB50 containing an in-frame deletion of the adenylate cyclase toxin gene (cyaA), was constructed with an in-frame deletion of the ATPase (bscN) gene required for type III secretion (Mann et al., 2007).
  • Immunization Route: intranasal immunization
Host Response

Mouse Response

  • Persistence: TLR4def and TNF-α−/− mice were intranasally inoculated with 103, 104, or 105 CFU of RB50 or 105 CFU of AVS in a 50-μl inoculum and observed them for signs of severe disease. WT mice given similar doses of RB50 are able to control the disease and to clear bacteria from the lower respiratory tract (Mann et al., 2007).
  • Efficacy: The nasal cavities of vaccinated TLR4def mice and TNF-α−/− mice contained 10,000-fold fewer CFU than those of control mice. The tracheae and lungs of vaccinated TLR4def mice and TNF-α−/− mice contained <20 CFU, while the same organs of control mice contained approximately 106 and 108 CFU, respectively. These results indicate that low-dose intranasal vaccination with AVS protects susceptible mice from severe infection by a variety of B. bronchiseptica strains (Mann et al., 2007).
  • Host Ifng (Interferon gamma) response
    • Description: AVS induces significantly increased IFN-gamma production in mouse splenocytes as compared to naive mice. This increase occurred 28 days after vaccination and after stimulation with heat-killed RB50 (Mann et al., 2007).
    • Detailed Gene Information: Click Here.
  • Host Il10 (interleukin 10) response
    • Description: AVS induces decreased IL-10 production in mouse splenocytes as compared to inoculation with wild type strain. This decrease occurred 28 days after vaccination and after stimulation with heat-killed RB50. However, IL-10 was significantly upregulated in splenocytes compared to naive mice (Mann et al., 2007).
    • Detailed Gene Information: Click Here.
References
Mann et al., 2007: Mann P, Goebel E, Barbarich J, Pilione M, Kennett M, Harvill E. Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine. Infection and immunity. 2007; 75(7); 3665-3672. [PubMed: 17452472].